2.40 USD
-0.11
4.38%
At close Apr 1, 4:00 PM EDT
After hours
2.40
+0.00
0.00%
1 day
-4.38%
5 days
-21.82%
1 month
-29.82%
3 months
-11.44%
6 months
-33.70%
Year to date
-11.44%
1 year
-57.22%
5 years
-88.88%
10 years
-88.88%
 

About: Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.

Employees: 157

0
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 4 analysts

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

121% more call options, than puts

Call options by funds: $850K | Put options by funds: $384K

55% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 22

27% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 33

7% more funds holding

Funds holding: 122 [Q3] → 131 (+9) [Q4]

0.52% more ownership

Funds ownership: 63.79% [Q3] → 64.31% (+0.52%) [Q4]

30% less capital invested

Capital invested by funds: $277M [Q3] → $194M (-$83.2M) [Q4]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$5
108%
upside
Avg. target
$7.75
223%
upside
High target
$10
317%
upside

4 analyst ratings

positive
100%
neutral
0%
negative
0%
Guggenheim
Vamil Divan
35% 1-year accuracy
9 / 26 met price target
317%upside
$10
Buy
Reiterated
20 Mar 2025
Needham
Gil Blum
7% 1-year accuracy
12 / 162 met price target
275%upside
$9
Buy
Reiterated
19 Mar 2025
HC Wainwright & Co.
Swayampakula Ramakanth
22% 1-year accuracy
45 / 203 met price target
192%upside
$7
Buy
Reiterated
19 Mar 2025
Keybanc
Scott Schoenhaus
26% 1-year accuracy
8 / 31 met price target
108%upside
$5
Overweight
Maintained
8 Jan 2025

Financial journalist opinion

Based on 8 articles about ABSI published over the past 30 days

Positive
MarketBeat
1 day ago
Which Healthcare Stock Is the Best Buy Right Now?
In the world of upstart pharmaceuticals and healthcare companies, timing is everything. These firms often struggle for an extended period of time before becoming profitable, but when they see success with a new product—or even clinical trial results suggesting a new product could be on the horizon—they can experience huge rallies in a very short period of time.
Which Healthcare Stock Is the Best Buy Right Now?
Neutral
GlobeNewsWire
6 days ago
Absci to Participate in Upcoming Investor Conferences
VANCOUVER, Wash. and NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the following upcoming investor conferences.
Absci to Participate in Upcoming Investor Conferences
Negative
Benzinga
1 week ago
Absci Posts Downbeat Results, Joins HealthEquity, Tonix Pharmaceuticals And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining around 0.2% on Wednesday.
Absci Posts Downbeat Results, Joins HealthEquity, Tonix Pharmaceuticals And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Neutral
Seeking Alpha
1 week ago
Absci Corporation (ABSI) Q4 2024 Earnings Call Transcript
Absci Corporation (NASDAQ:ABSI ) Q4 2024 Earnings Conference Call March 18, 2025 4:30 PM ET Company Participants Alex Khan - VP of Finance and IR Sean McClain - Founder and CEO Zach Jonasson - CFO and CBO Christian Stegmann - SVP of Drug Creation Conference Call Participants Arseniy Shabashvili - Guggenheim Vikram Purohit - Morgan Stanley Gil Blum - Needham & Company Debanjana Chatterjee - Jones Operator Thank you for standing by and welcome to Absci's Fourth Quarter and Full Year 2024 Business Update and Financial Operating Results Conference call. At this time, all participants are in listen-only mode.
Absci Corporation (ABSI) Q4 2024 Earnings Call Transcript
Neutral
GlobeNewsWire
2 weeks ago
Absci Reports Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results
Unveiled updates across proprietary pipeline and demonstrated new breakthroughs by AI platform at 2024 R&D Day Entered into collaboration with AMD, including $20 million strategic investment in Absci Achieved 2024 outlook for drug creation partnerships through collaborations with Owkin, Twist Bioscience, Invetx, and Memorial Sloan Kettering Cancer Center Cash, cash equivalents, and short-term investments sufficient to fund operations into the first half of 2027 VANCOUVER, Wash. and NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today reported financial and operating results for the quarter and full year ended December 31, 2024.
Absci Reports Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results
Neutral
GlobeNewsWire
3 weeks ago
Absci to Report Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results on March 18, 2025
VANCOUVER, Wash. and NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for the fourth quarter and full year 2024 after market close on Tuesday, March 18, 2025.
Absci to Report Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results on March 18, 2025
Neutral
GlobeNewsWire
3 weeks ago
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
VANCOUVER, Wash. and NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced that on March 3, 2025, the company granted a non-statutory stock option to purchase an aggregate of 162,800 shares of its common stock to one newly-hired non-executive employee. The inducement grant was previously approved by the Compensation Committee of Absci's Board of Directors pursuant to Absci's 2023 Inducement Plan (the “Inducement Plan”), and is being made as an inducement material to the new employee's acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Neutral
GlobeNewsWire
4 weeks ago
Absci to Participate in the KeyBanc Capital Markets Healthcare Forum
VANCOUVER, Wash. and NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming virtual KeyBanc Capital Markets Healthcare Forum.
Absci to Participate in the KeyBanc Capital Markets Healthcare Forum
Neutral
GlobeNewsWire
1 month ago
Absci to Participate in the TD Cowen 45th Annual Health Care Conference
VANCOUVER, Wash. and NEW YORK, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming TD Cowen 45th Annual Health Care Conference in Boston, MA.
Absci to Participate in the TD Cowen 45th Annual Health Care Conference
Positive
Benzinga
2 months ago
Analyst Praises AMD-Partner Absci's Practical Approach, Sees 118% Stock Upside
Needham analyst has initiated coverage on Absci Corporation ABSI, a drug and target discovery company that harnesses deep learning AI and synthetic biology to expand proteins' therapeutic potential.
Analyst Praises AMD-Partner Absci's Practical Approach, Sees 118% Stock Upside
Charts implemented using Lightweight Charts™